KeyBanc analyst Scott Schoenhaus maintains $Recursion Pharmaceuticals (RXRX.US)$ with a buy rating, and adjusts the target price from $12 to $10.
According to TipRanks data, the analyst has a success rate of 37.1% and a total average return of -2.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Recursion Pharmaceuticals (RXRX.US)$'s main analysts recently are as follows:
Political and rate uncertainty persist as concerns, yet the general condition of the Biopharma sector is seen as significantly better compared to its lowest points in 2022. Analysts express a preference for stocks that feature late-stage clinical or early launch narratives. Additionally, those in Phase 1 clinical programs that present derisking data along with near-term catalysts are gaining growing attention among investors.
The firm highlighted that healthcare technology stocks experienced significant pressure throughout much of last year but witnessed a rebound in the final two months following the presidential election. Alongside cuts to consensus estimates since mid-last year, the analyst deems 2025 as presenting attractive investment opportunities within the sector. From the standpoint of valuation multiples, the analyst surmises that companies boasting robust balance sheets and consistent free cash flow will face diminished risks of multiple contraction amidst more subdued growth outlooks. On the flip side, they view companies with strained balance sheets and scant near-term profitability as carrying heightened risks moving forward.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
KeyBanc分析师Scott Schoenhaus维持$Recursion Pharmaceuticals (RXRX.US)$买入评级，并将目标价从12美元下调至10美元。
根据TipRanks数据显示，该分析师近一年总胜率为37.1%，总平均回报率为-2.7%。
此外，综合报道，$Recursion Pharmaceuticals (RXRX.US)$近期主要分析师观点如下：
政治和利率的不确定性仍然令人担忧，但与2022年的最低点相比，生物制药行业的总体状况被认为要好得多。分析师表示偏爱以后期临床或早期上市叙事为特色的股票。此外，那些在第一阶段临床项目中提供去风险数据和短期催化剂的人越来越受到投资者的关注。
该公司强调，医疗保健科技股在去年的大部分时间里都承受了巨大的压力，但在总统大选后的最后两个月中出现了反弹。除了自去年年中以来下调共识预期外，分析师还认为2025年为该行业提供了有吸引力的投资机会。从估值倍数的角度来看，分析师推测，在增长前景更加疲软的情况下，拥有强劲资产负债表和持续自由现金流的公司面临的多重收缩风险将降低。另一方面，他们认为资产负债表紧张且短期盈利能力不足的公司面临更大的未来风险。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
